Survival comparison of hepatocellular carcinoma patients treated with radioembolization versus nonoperative/interventional treatment

被引：7
|
作者：
Thayer, David [1 ]
Noda, Christopher [1 ]
Charalel, Resmi [1 ]
Mills, Abigail [1 ]
Chang, Randy [2 ]
Tao, Yu [3 ]
Akinwande, Olaguoke [1 ,4 ]
机构：
[1] Washington Univ, Mallinckrodt Inst Radiol, Div Intervent Radiol, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Div Intervent Radiol, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Siteman Biostat, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2018年 / 7卷 / 04期
关键词：
advanced hepatocellular carcinoma; comparative effectiveness; hazard ratio; liver cancer-specific survival; nonoperative treatment; overall survival; palliation; prognostic prediction; TRANSARTERIAL CHEMOEMBOLIZATION; LIVER-TRANSPLANTATION; COHORT; MULTICENTER; SORAFENIB; RESECTION; THERAPY;
D O I：
10.2217/cer-2017-0064
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: To compare the overall survival (OS) and liver cancer-specific survival of advanced-stage hepatocellular carcinoma (HCC) patients who received transarterial radioembolization (TARE) with those who received nonoperative/interventional treatment (NOT). Materials & methods: A total of 12,520 HCC patients from the Surveillance, Epidemiology and End Results database were categorized by treatment with either radioembolization or NOT. Kaplan-Meier and multivariate Cox regression were conducted. Results: The TARE group had both a significantly longer median overall survival than the NOT group (TARE = 9 months; NOT = 2 months; p < 0.0001) and a significantly higher probability of liver cancer-specific survival (hazard ratio = 0.474). Conclusion: TARE appears to provide a significant survival advantage over the NOT population in advanced HCC patients.
引用
收藏
页码：343 / 356
页数：14
相关论文
共 50 条
  • [31] Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization
    Salem, Riad
    Gilbertsen, Margaret
    Butt, Zeeshan
    Memon, Khairuddin
    Vouche, Michael
    Hickey, Ryan
    Baker, Talia
    Abecassis, Michael M.
    Atassi, Rohi
    Riaz, Ahsun
    Cella, David
    Burns, James L.
    Ganger, Daniel
    Benson, Al B., III
    Mulcahy, Mary F.
    Kulik, Laura
    Lewandowski, Robert
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (10) : 1358 - +
  • [32] COMPARISON OF OVERALL SURVIVAL ACCORDING TO THE ELIGIBILITY OF PRETREATMENT STUDY OF TRANSARTERIAL RADIOEMBOLIZATION FOR LARGE HEPATOCELLULAR CARCINOMA
    Cho, Heejin
    Chung, Sung Won
    Shin, Hyunjae
    Park, Jeayeon
    Kim, Ju Yeon
    Hong, Ji Hoon
    Hur, Moon Haeng
    Park, Min Kyung
    Bin Lee, Yun
    Cho, Eun Ju
    Yu, Su Jong
    Lee, Myungsu
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    Chung, Jin Wook
    Lee, Jeong-Hoon
    Kim, Hyo-Cheol
    HEPATOLOGY, 2022, 76 : S1360 - S1361
  • [33] Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization
    Kim, Yuna
    Lee, Jae Seung
    Lee, Hye Won
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Kim, Seung Up
    CURRENT ONCOLOGY, 2021, 28 (01) : 965 - 977
  • [34] Predictors of good outcomes in patients with hepatocellular carcinoma (HCC) treated with transarterial radioembolization (TARE)
    Das, Parthib
    Paul, Samuel
    Min, Eric
    Mittra, Arjun
    Malalur, Pannaga G.
    Manne, Ashish
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization
    Lee, Jae Seung
    Lee, Han Ah
    Jeon, Mi Young
    Lim, Tae Seop
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Young
    Ahn, Sang Hoon
    Um, Soon Ho
    Han, Kwang-Hyub
    Seo, Yeon Seok
    Kim, Seung Up
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 32 (06) : 739 - 747
  • [36] ALBI grade for outcome prediction in patients affected by hepatocellular carcinoma treated with transarterial radioembolization
    Gelardi, Fabrizia
    Rodari, Marcello
    Pini, Cristiano
    Zanca, Roberta
    Artesani, Alessia
    Tosi, Giovanni
    Chiti, Arturo
    Sollini, Martina
    FRONTIERS IN NUCLEAR MEDICINE, 2022, 2
  • [37] Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization Prediction by 18F-FDG PET
    Sabet, A.
    Ahmadzadehfar, H.
    Bruhman, J.
    Sabet, A.
    Meyer, C.
    Wasmuth, J. -C.
    Pieper, C. -C.
    Biersack, H. -J.
    Ezziddin, S.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2014, 53 (02): : 39 - 45
  • [38] Usefulness of AFP, DCP, and Modified RECIST Responses to Predict Survival for Patients with Hepatocellular Carcinoma Treated with Transarterial Radioembolization: A Landmark Analysis
    Lim, Tae Seop
    Rhee, Hyungjin
    Kim, Beom Kyung
    Kim, Seung Up
    Park, Jun Yong
    Ahn, Sang Hoon
    Han, Kwang-Hyub
    Choi, Jin-Young
    Kim, Do Young
    HEPATOLOGY, 2018, 68 : 866A - 866A
  • [39] Patterns of Care and Survival Outcomes between Patients with Unresected Hepatocellular Carcinoma Treated with External Beam Vs Radioembolization in the SEER Database
    Chitti, B. S.
    Scher, D.
    Chun, A.
    Sarin, S.
    Goyal, S.
    Rao, Y. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E217 - E217
  • [40] European multicenter evaluation of survival for patients with hepatocellular carcinoma (HCC) treated by radioembolization with 90y-labeled resin microspheres
    Sangro, B.
    Carpanese, L.
    Cianni, R.
    Golfieri, R.
    Gasparini, D.
    Ezzidin, S.
    Hoffman, R.
    Fiore, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345